%0 Journal Article
%T Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.
%A Wang Z
%A Lu Y
%A Han M
%A Li A
%A Ruan M
%A Tong Y
%A Yang C
%A Zhang X
%A Zhu C
%A Wang C
%A Shen K
%A Dong L
%A Chen X
%J Breast Cancer Res Treat
%V 0
%N 0
%D 2024 Jul 24
%M 39048852
%F 4.624
%R 10.1007/s10549-024-07436-1
%X <B>BACKGROUND: </B>The aim of this study was to assess homologous recombination deficiency (HRD) status and its correlation with carboplatin treatment response in early triple-negative breast cancer (TNBC) patients.<BR><B>METHODS: </B>Tumor tissues from 225 consecutive TNBC patients were evaluated with an HRD panel and homologous recombination-related (HRR) gene expression data. HRD positivity was defined as a high HRD score and/or BRCA1/2 pathogenic or likely pathogenic mutation. Clinicopathological factors, neoadjuvant treatment response, and prognosis were analyzed with respect to HRD status in these TNBC patients.<BR><B>RESULTS: </B>HRD positivity was found in 53.3% of patients and was significantly related to high Ki67 levels (P = 0.001). In patients who received neoadjuvant chemotherapy, HRD positivity (P = 0.005) or a high HRD score (P = 0.003) was significantly associated with a greater pathological complete response (pCR) rate, especially in those treated with carboplatin-containing neoadjuvant regimens (HRD positivity vs. negativity: 50.00% vs. 17.65%, P = 0.040). HRD positivity was associated with favorable distant metastasis-free survival (hazard ratio HR 0.49, 95% confidence interval CI 0.26-0.90, P = 0.022) and overall survival (HR 0.45, 95% CI 0.20-0.99, P = 0.049), irrespective of carboplatin treatment.<BR><B>CONCLUSIONS: </B>TNBC patients with high HRDs had high Ki67 levels and BRCA mutations. HRD-positive TNBC patients treated with carboplatin had a higher pCR rate. Patients with HRD positivity had a better prognosis, irrespective of carboplatin treatment, warranting further evaluation.